Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Conditions
Brief summary
This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. Giving enzalutamide, radiation therapy, and hormone therapy may be an effective treatment for prostate cancer.
Detailed description
PRIMARY OBJECTIVE: 1\) To assess the safety of the combination of neoadjuvant and concurrent enzalutamide with an luteinizing-hormone-releasing hormone (LHRH) agonist and radiation therapy. SECONDARY OBJECTIVES: 1. To determine the efficacy of the combination of enzalutamide with an LHRH agonist and radiation therapy using prostate specific antigen (PSA) kinetics. 2. To determine the efficacy of the combination of enzalutamide with an LHRH agonist and radiation therapy using PSA nadir. 3. To describe patient-reported outcomes including: Expanded Prostate Cancer Index Composite (EPIC), American Urological Association (AUA) Symptom Index, PROstate magnetic resonance (MR) Imaging Study (PROMIS) Fatigue Scale. OUTLINE: Patients receive enzalutamide orally (PO) once daily (QD) for 6 months. Beginning 2 weeks after start of enzalutamide, patients receive LHRH agonist therapy with goserelin acetate subcutaneously (SC) or leuprolide acetate intramuscularly (IM) or SC for 6 months (intermediate risk patients) or 24 months (high risk patients) post-radiation therapy. Beginning 8 weeks after the start of LHRH agonist therapy, patients undergo either intensity modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) daily five days a week for 8 weeks. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
Interventions
DRUGEnzalutamide
Given PO
DRUGGoserelin acetate
Given SC
DRUGLeuprolide acetate
Given IM or SC
RADIATIONRadiation therapy
Undergo image-guided radiation therapy
Sponsors
Astellas Pharma Inc
Medivation, Inc.
Thomas Jefferson University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Prostate adenocarcinoma without distant metastatic disease with either Gleason score ≥ 7, PSA ≥ 10 ng/ml, or T2b or greater disease 2. Age \> 18 3. Performance Status: ECOG 0-1 4. Hematologic (minimal values): * Absolute neutrophil count \> 1,500/mm3 * Hemoglobin \> 8.0 g/dl * Platelet count \> 100,000/mm3 5. Hepatic function * Total bilirubin \< Upper limit of normal (ULN)(except for Gilbert's disease) * AST (SGOT) \< 1.5 x ULN * ALT (SGPT) \< 1.5 x ULN 6. Creatinine \< 1.5 x ULN 7. Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter.
Exclusion criteria
1. Patients with a history of seizure, underlying brain injury with loss of consciousness, transient ischemic attack within the past 12 months, cerebral vascular accident, brain metastases, brain arteriovenous malformation or the use of concomitant medications that may lower the seizure threshold 2. History of urological surgery or procedures predisposing to GU complications after radiation (will be determined by radiation oncologist) 3. History of diverticulitis, rectal bleeding or other lower GI diseases predisposing to GI complications after radiation (will be determined by radiation oncologist) 4. History of prior chemotherapy or pelvic irradiation, 5. History of prior invasive malignant cancer(s) within the last 5 years except adequately treated or controlled basal cell or squamous cell carcinoma of the skin. 6. Documented distant metastatic disease. NOTE: pelvic lymphadenopathy is NOT excluded. 7. Prior radical prostatectomy or cryosurgery for prostate cancer or bilateral orchiectomy. 8. No experimental medications within 30 days of study entry 9. Patients currently taking the following medications: * CYP2C8 inhibitors (e.g. Gemfibrozil) * CYP2C8 inducers (e.g. rifampin) * CYP3A4 inhibitors (itraconazole) * CYP3A4 inducers (e.g., carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, rifapentine)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute toxicities, monitored using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 criteria | Up to 1 month post completion of enzalutamide | An exact 2-sided binomial 90% confidence interval will be computed and reported. Toxicity will be monitored and if there is greater than 10% incidence of grade 3 or higher gastrointestinal (GI)/genitourinary (GU)/fatigue lasting more than 7 days despite optimal treatment, the trial will be re-evaluated. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in PSA levels | Baseline up to 6 months | Evaluated using linear mixed models. Mixed models will make use of all available data, and can estimate individual levels of change. |
| Quality of life (QoL), measured using the EPIC, AUA symptom index, and the PROMIS Fatigue Scale | Baseline up to 1 year | QoL measures will also be assessed via linear mixed models, as an exploratory evaluation of potential clinical correlates, such as age, race, stage, Gleason score, etc. |
Countries
United States
Outcome results
None listed